Major Victory For CAR T-Cell Therapy in Multiple Myeloma FDA Advisory Panel Support For Abecma and Carvykti Therapies Earlier in The Disease Course, Despite Safety Concerns

Multiple myeloma treatments -Abecma & Carvykti - that raised concerns among regulators because of an increased rate of “early deaths” during clinical trials managed to get a unanimous vote from the U.S. Food and Drug Administration FDA to move forward with development, citing that the benefits outweigh the risks.